Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI lifestyle coach tested for prediabetes: a 28-Day digital health experiment

NCT ID NCT07160985

Disease control Sponsor: Li Huating Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial tested whether an AI-powered system called X Life could help adults with prediabetes improve their blood sugar control. Over 28 days, 131 participants either used the AI system for real-time diet and exercise recommendations or received standard lifestyle advice. The study measured changes in glucose tolerance to see if the AI approach was more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based lifestyle management system (X Life)
What this could lead to
If it works, this could point toward a practical, non-drug tool to help people with prediabetes manage their blood sugar and potentially delay or prevent type 2 diabetes.
What could go wrong
This is a small, early-stage trial (131 people) testing a short-term intervention (28 days). The results may not be generalizable, and the AI system may not lead to lasting improvements or be better than standard lifestyle advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

131 people

The number who actually took part.

Started

Sep 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-70 years * Prediabetes (per ADA or WHO criteria) * Stable lifestyle and body weight (±5%) for ≥3 months * Owns and can operate a smartphone * Able to understand and sign informed consent Exclusion Criteria: * Current glucose-lowering medication use * Severe cardiovascular disease, liver/kidney dysfunction, or active malignancy * Psychiatric or cognitive disorders affecting participation * Planned major surgery or long-distance travel during the study * Allergy/intolerance to CGM sensor materials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre diabetes

Contacts and locations

Locations

  • Shanghai Sixth People's Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.